

Limited Submission Funding Opportunities – updated 3/05/21

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Clinical and Translational Science Award (U54 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/pa-files/PAR-18-940.html>

MGH LOI Deadline: 3/05/21

NIH LOI Deadline: 3/15/21

NIH Application Deadline: 4/15/21

The purpose of this funding opportunity announcement (FOA) is to invite applications to participate in the Clinical and Translational Science Award (CTSA) Program which supports high quality translational science and clinical research locally, regionally and nationally and fosters innovation in research methods, training, and career development.

Limited Submission Funding Opportunities – updated 3/05/21

2. NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center (U24 Clinical Trial Not Allowed) – NEW!

<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-019.html>

MGH LOI Deadline: 3/10/21

NIH LOI Deadline: 3/23/21

NIH Application Deadline: 4/23/21

The purpose of the NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Coordination and Evaluation Center (CEC), is to coordinate and facilitate the development of strategies with FIRST Cohort awardees to conduct a comprehensive evaluation of the FIRST program.

3. Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-001.html>

MGH LOI Deadline: 4/12/21

NIH LOI Deadline: 5/15/21

NIH Application Deadline: 6/15/21

The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.

4. Human Immunology Project Consortium (HIPC) (U19 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-079.html>

MGH LOI Deadline: 4/13/21

NIH LOI Deadline: 5/4/21

NIH Application Deadline: 6/4/21

This Funding Opportunity Announcement (FOA) for the Human Immunology Project Consortium (HIPC) solicits applications from single institutions, or consortia of institutions, to participate in a network of human immunology profiling research groups in the area of infectious diseases, including HIV. The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, vaccine adjuvants or natural infections by capitalizing on recent advances in immune profiling technologies. Studies supported under this FOA will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The resulting data will be used to develop molecular signatures that define immune response profiles and identify biomarkers that correlate with the outcomes of vaccinations, vaccine adjuvants or natural infections in humans. An additional goal of this program is to promote rapid public access to HIPC-supported data and meta-data through public portals such as ImmPort. A companion FOA will support development and operation of a HIPC Coordinating Center that will be responsible for fostering collaborations amongst HIPC-funded investigators; facilitating public dissemination of integrated HIPC findings and knowledge; and supporting development or adoption of new, robust methods for data integration, analysis, presentation, and visualization to further research and development in this field.

Limited Submission Funding Opportunities – updated 3/05/21

5. Human Immunology Project Consortium (HIPC) Coordinating Center (U01 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-080.html>

MGH LOI Deadline: 4/13/21

NIH LOI Deadline: 5/4/21

NIH Application Deadline: 6/4/21

The goal of this FOA is to support a Coordinating Center for the Human Immunology Project Consortium (HIPC) program. The HIPC program, supported through a separate FOA, will consist of 5-8 multi-project cooperative agreement (U19) awardees that will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The HIPC Coordinating Center supported by this FOA will be responsible for: coordinating cross-HIPC data integration, analysis, and visualization; developing and maintaining a public HIPC website and knowledgebase to support cross-HIPC data analysis and visualization; and fostering collaborations amongst HIPC-funded investigators by managing the HIPC subcommittees and an Infrastructure and Opportunity Fund to support collaborative studies.

6. Screening for Conditions by Electronic Nose Technology (SCENT) (U01 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-009.html>

MGH LOI Deadline: 4/13/21

NIH LOI Deadline: 5/10/21

NIH Application Deadline: 6/10/21

This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin and to develop a catalog of VOCs as distinct signatures for at least 20 human diseases and conditions. These sensing devices must be able to associate VOC patterns using artificial intelligence to patients with various conditions for diagnostic purposes along with capabilities to incorporate and integrate vital signs. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology, Gas Chromatography (GC) or any sensing technology able to detect VOC patterns associated with disease. This new program is called SCENT, which stands for Screening for Conditions by E-Nose Technology.

To ensure project success, this FOA requires multidisciplinary collaborations and a team science approach. Groups may include a combination of the following: Biomedical engineers, material scientists, biosensing experts, software engineers, chemists, clinicians, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry.

7. Maximizing Access to Research Careers (T34) – NEW!

<https://grants.nih.gov/grants/guide/pa-files/PAR-21-147.html>

MGH LOI Deadline: 4/20/21

NIH Application Deadline: 5/26/21

The goal of the Maximizing Access to Research Careers (MARC) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed

Limited Submission Funding Opportunities – updated 3/05/21

research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at baccalaureate degree-granting research-intensive institutions (i.e., those with an average of NIH Research Project Grant funding greater than or equal to \$7.5 million total costs over the last 3 fiscal years).

This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

8. Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)

<https://grants.nih.gov/grants/guide/pa-files/PAR-21-146.html>

MGH LOI Deadline: 4/21/21

NIH Application Deadline: 5/26/21

The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at baccalaureate degree-granting research-active institutions (i.e., those with an average of NIH Research Project Grant funding less than \$7.5 million total costs over the last 3 fiscal years).

This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

9. New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (UG3/UH3 Clinical Trials Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-001.html>

MGH LOI Deadline: 5/04/21

NIH LOI Deadline: 6/08/21

NIH Application Deadline: 7/08/21

The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA will support intramural - extramural collaborations to develop additional physical modules that will enhance the platform's capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.